Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN223504 - Provider product page
- Provider
- antibodies-online
- Proper citation
- Antibodies-Online Cat#ABIN223504, RRID:AB_10849787
- Product name
- anti-Low Density Lipoprotein Receptor (LDLR) antibody
- Antibody type
- Polyclonal
- Description
- Affinity purified
- Reactivity
- Human, Mouse, Rat, Bovine, Hamster
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 μg
- Storage
- For long-term storage, aliquot and freeze at -70°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression.
Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.
High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters.
Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.
Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
Dong B, Li H, Singh AB, Cao A, Liu J
The Journal of biological chemistry 2015 Feb 13;290(7):4047-58
The Journal of biological chemistry 2015 Feb 13;290(7):4047-58
Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
Shende VR, Wu M, Singh AB, Dong B, Kan CF, Liu J
Journal of lipid research 2015 Apr;56(4):801-9
Journal of lipid research 2015 Apr;56(4):801-9
A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression.
Singh AB, Kan CF, Shende V, Dong B, Liu J
Journal of lipid research 2014 May 2;55(7):1397-1407
Journal of lipid research 2014 May 2;55(7):1397-1407
Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.
Trushina E, Canaria CA, Lee DY, McMurray CT
Human molecular genetics 2014 Jan 1;23(1):129-44
Human molecular genetics 2014 Jan 1;23(1):129-44
High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters.
Briand F, Thiéblemont Q, Muzotte E, Sulpice T
The Journal of nutrition 2012 Apr;142(4):704-9
The Journal of nutrition 2012 Apr;142(4):704-9
Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.
Cao A, Wu M, Li H, Liu J
Journal of lipid research 2011 Mar;52(3):518-30
Journal of lipid research 2011 Mar;52(3):518-30
Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW, Liu J
Journal of lipid research 2010 Jun;51(6):1486-95
Journal of lipid research 2010 Jun;51(6):1486-95
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
